PATENT CLAIM ANALYSIS

Application Number: 16009372
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "465000"]

Abstract:
A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

Claim (Index 3):
The composition of  claim 1 , wherein the dosage form is a buccal or sublingual tablet, which is at least 20% w/w of the acid.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 94.0
- Lexical Diversity: 1.95652
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13633924', '14634689', '15148106', '14978459', '11060641']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7668061647112348
- 35 USC 102 Novelty (BERT): 0.5122858365394579
- Combined Prediction Score: 0.7413541318940571
- Mean Citation Score: 264.33231
- Max Citation Score: 290.1086
- Similarity Product: 207.2663951696396

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test